{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-269400","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2024-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.933682+00:00","generated_at":"2026-05-29T09:51:55.199428+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Elicio Therapeutics completes enrollment of 135 patients in Phase 2 AMPLIFY-7P study for ELI-002","bullets":["Phase 2 study ELI-002 7P enrolled 135 mKRAS-driven PDAC patients post-surgery, randomized 2:1 vs observation.","Interim analysis of disease-free survival (DFS) expected in H1 2025, with possible final analysis in H2 2025.","Enrollment pace exceeded expectations; patients eligible cross-over to ELI-002 upon progression.","Primary endpoint is DFS; key secondary endpoints include overall survival and vaccine immunogenicity.","Previous Phase 1a data showed favorable safety and T-cell responses; SITC 2024 data presented."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-269400","json":"https://secwatch.observer/filing/0001193125-24-269400.json","markdown":"https://secwatch.observer/filing/0001193125-24-269400.md","text":"https://secwatch.observer/filing/0001193125-24-269400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000119312524269400/0001193125-24-269400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000119312524269400/d858884d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T09:51:55.199428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}